Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer

NCT04856371 is registered in ClinicalTrials.gov with Haihe Biopharma Co., Ltd. as lead sponsor.

NCT NCT04856371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04856371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer
Lead sponsor
Haihe Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2021
Completion date
December 31, 2022
Enrollment
228 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer